Bharat Biotech to begin supplies of GSK's malaria vaccine RTS.S to GAVI in 2026
The supplies form part of pledges by both companies to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030), the Hyderabad-based vaccine maker said on Wednesday, announcing it will also progressively reduce price of the vaccine by more than half to less than $5 by 2028.
Process improvements, expanded production capacity, cost-effective manufacturing and minimal profit margins will be factors driving down the price, it said.
RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021.
Technology transfer
Since then, GSK has made significant investments to enhance production capacity and efficiency and to undertake the planned technology transfer to Bharat Biotech, which in parallel, invested over $200 million in new, higher-output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete, it said.
With Gavi's support, 12 endemic countries in Africa will introduce RTS,S through routine immunisation programmes by 2025.
'By joining forces with GSK and working closely with Gavi and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria,' Bharat Biotech Executive Chairman Krishna Ella said.
GSK's Chief Global Health Officer Thomas Breuer said 'We partnered with Bharat Biotech in 2021 with a common goal... Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO.'
The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the pledge to the Gavi replenishment, he said.
'Our ambition is to protect at least 50 million more children across Africa by the end of 2030 and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach,' Gavi CEO Sania Nishtar said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
6 hours ago
- Indian Express
Man falls to death from 18th floor in Wadala
A 55-YEAR-OLD man who was suffering from dysentery fell from the 18th floor into the elevator in a Wadala-based building. The deceased, identified as Prakash Shinde, had gone to answer nature's call when he fell to his death. An Accidental Death Report has been filed by the police in the case. An officer from RAK Marg police station said that Shinde had gone to stay at his sister's house a couple of days ago in Wadala. He was reportedly suffering from dysentery and wanted to go to the washroom. However, since it was already occupied, he came near the lift area where lift work was going on. An official said that he defecated near the pit and while he was getting up, he lost his balance and fell into the pit. A fire brigade team was called that rescued him. He was rushed to the KEM hospital where he was declared dead on arrival. An officer said the family members did not suspect any foul play and they have filed an accidental death report in the matter.
The Print
7 hours ago
- The Print
Dermatologist & ThePrint columnist Dr Deepali Bhardwaj honoured by IMA for exemplary community service
Besides running her own clinic, Dr Bhardwaj is actively involved with the Deepanjan Charitable Trust, which operates in Delhi NCR. The trust provides free medical assistance and guidance to people living below the poverty line, with special focus on women's health. She has been working in the field for over 10 years and this was the first time she was nominated for the award. 'This kind of award not only motivates doctors, but also gives a sense of recognition to those who are genuinely working—not just doing things for social media,' Dr Bhardwaj told ThePrint. New Delhi: The Indian Medical Association (IMA) held its annual award ceremony Sunday to mark Doctors' Day, celebrating exemplary contributions by doctors from across the country. Among the key awardees this year is Dr Deepali Bhardwaj, a Delhi-based dermatologist and public health advocate. Dr Bhardwaj, who is a columnist for ThePrint, was honoured under the Community Service category. National Doctors' Day is observed on 1 July every year to commemorate the birth and death anniversaries of visionary leader, social reformer, renowned physician and former chief minister of West Bengal, Dr. Bidhan Chandra Roy. The awards are instituted by IMA in his honour. The event was held at the Institute of Town Planners, India, in New Delhi. Medical professionals from various states were honoured for their commitment to both clinical excellence and community service across multiple categories, including Community Service, Public Health, Academic Contributions and Lifetime Achievement. Besides Dr Bhardwaj, other awardees in the Community Service category are Dr Shaili Vyas, community medicine specialist from Uttarakhand, Dr Prakash Jagdish Bhai from Gujarat awarded for organising over a dozen health camps and blood donation drives, and Dr Ashish Aneja from Haryana honoured for diabetes care and outreach for the underprivileged. The chief guest at Sunday's event was Union Minister of State (Independent Charge) for Science and Technology Dr Jitendra Singh. Other distinguished guests included Dr Anil Goyal, Delhi MLA and managing director of Goyal Hospital Neurology Centre, and Dr Piyush Jain, Honorary Finance Secretary of the IMA. Dr Goyal, a senior urologist, delivered his keynote address emphasising the need for doctors to reclaim their public image, and urged medical professionals to use modern platforms to share their stories and contributions. The MLA criticised politicians who accuse doctors of malpractices, despite their efforts to provide affordable, accessible, and quality healthcare across the country. 'We must document our work through videos, podcasts, articles, and anecdotes—anything that highlights our contribution and hard work. The public needs to hear about real doctors doing real work,' he said. '(PM) Modi ji is also doing image makeovers—every minute, every day. So, we too need to work on our own image.' Speaking about the importance of the annual awards, Dr Goyal added that these kinds of honours and recognitions strengthen the trust between doctors and society, and tell people that doctors are not just medical professionals, but also community builders. The event concluded with the observation of minute-long silence in memory of the doctors and medical staff at the B.J. Medical College, who lost their lives or were injured in the tragic Air India crash in Ahmedabad on 12 June. (Edited by Mannat Chugh) Also Read: Are Homeopaths, Ayurvedic practitioners doctors? Grandmaster's spat with 'Liver Doc' revives debate
Mint
9 hours ago
- Mint
Proxy adviser seeks update on ₹480 cr ESOP clawback from Rashmi Saluja
Mumbai: Five months after Dabur India Ltd chairman Mohit Burman took control of Religare Enterprises Ltd, a proxy advisory firm has sought an update on the issue of recovering shares of a subsidiary worth ₹ 480 crore from former Religare chair Rashmi Saluja. On Sunday, InGovern Research Services issued a note asking that Religare and its subsidiary, Care Health Insurance, provide details and an update on the employee share options awarded to Saluja. The Bengaluru-based proxy advisor also asked for the recovery of fees paid by Care Health to its former independent director, Pratap Venugopal, who provided legal opinion to the insurance firm. When contacted, Religare on Sunday said, 'Irdai issued an order holding the issuance of ESOPs to Dr Saluja illegal. Care Health Insurance Limited had filed an appeal before the Securities Appellate Tribunal (SAT) under instructions from Dr Saluja, who was then the non-executive chairperson of the board. Subsequent to Dr. Saluja's removal from the board, the board of directors of the company decided to withdraw the appeal. The said appeal before the SAT now stands withdrawn. We offer no further comments as these issues are being examined internally.' Saluja received ESOP grants representing about 2.5% of Care's share capital. More than four-fifths of the insurance firm's ESOPs were allotted to her. InGovern has also raised conflict of interest concerns about Venugopal, a senior advocate, counselling Care Insurance on the ESOPs, as he was also an independent director on the company's board. Venugopal was advising and approving Care's decisions on the ESOPs, as per InGovern. As per the proxy adviser's report, the Nomination and Remuneration Committee, which approves pay and stock options, also lacked independence as Venugopal was a part of it. The dual role of Venugopal was not clearly disclosed to shareholders, InGovern said. 'Venugopal played dual roles, as an advisor and an ID (independent director), in a critical matter like the issuance of ESOPs, especially after IRDAI had disapproved the issuance of ESOPs, yet the company relied on his legal opinion to proceed with it,' said Shriram Subramanian, managing director of InGovern. Such roles create potential conflict of interest in list companies if full disclosures are not made, he said. Mint could not immediately reach Venugopal for comment. Religare owns 62.91% of Care Health, while Kedaara Capital and Union Bank of India own 15.84% and 5.28%, respectively. Public shareholders own the remaining 16%. The issue raised by InGovern is about the grant of 22.7 million ESOPs by Care Health to Saluja, a non-executive director at the time, even after the Insurance Regulator and Development Authority of India rejected the proposal. Saluja had exercised 7.57 million of those options. In July 2024, IRDAI took action and imposed a ₹ 1 crore penalty on Care Health and ordered the company to buy back the 7.57 million exercised shares at ₹ 45.32 each within 30 days and cancel all unvested ESOPs within 15 days. IRDAI had found the grants in violation of Section 34A of the Insurance Act. Section 34A of the Indian Insurance Act, 1938 gives IRDAI the authority to approve the appointment, reappointment, termination, and remuneration of key managerial personnel in insurance companies. InGovern has now demanded a public disclosure of the minutes of the board and Nomination and Remuneration Committee meetings, legal opinions on ESOPs, full IRDAI correspondence, and conflict of interest declarations. At the regulatory level, the proxy adviser has called for a probe by the Securities and Exchange Board of India into disclosure lapses and a review by the ministry of corporate affairs into director roles and responsibilities.
